Featured News

View ASX Announcements here.

Starpharma announces positive final DEP® irinotecan Phase 2 clinical trial results (ASX Announcement)

May 27th, 2024

Starpharma announces the full results of the Phase 2 open-label clinical trial of DEP® irinotecan. The trial met its objectives, with endpoints demonstrating positive anti-tumour efficacy of DEP® irinotecan in heavily pre-treated patients with a range of difficult-to-treat, advanced, metastatic cancers, including colorectal cancer (CRC) and platinum-resistant ovarian cancer.

Read More

Investor Webinar - Starpharma Business Update (22 May 2024)

May 24th, 2024

Starpharma hosted an investor webinar on Wednesday, 22 May 2024, to provide shareholders with a business update. 

Starpharma’s CEO, Cheryl Maley, hosted the webinar, alongside the CFO and Company Secretary, Justin Cahill, VP of Business Development, Dr Tony Eglezos, and VP of Development and Regulatory Affairs, Dr Jeremy Paull.

Read More

Starpharma Business Update (ASX Announcement)

May 22nd, 2024

Starpharma dedicated to helping patients with significant illness, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology, is pleased to provide shareholders with a business update following an extensive review of strategy and operations, led by Starpharma’s CEO, Cheryl Maley, alongside the leadership team and Board of Directors.

Read More

Investor Webinar Notification – Starpharma Business Update (ASX Announcement)

May 20th, 2024

Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce that it will host an investor webinar on Wednesday, 22 May 2024, to provide shareholders with a business update.

Read More

 

News

In the media

Ex-Novartis boss shines as CEO

May 23rd, 2024

"In less than five months at the helm of Starpharma, Cheryl Maley, has established a pathway to increase the company's revenue by "accelerating commercial opportunities" and "building stronger brands" for its existing products".

Read More

Which ASX companies are resurrecting abandoned drugs? Part 3

Apr 18th, 2024

"SPL has developed its proprietary Dendrimer Enhanced Products platform (DEP) to improve the effectiveness and safety of drugs, especially cancer treatments." Read the full article in Stockhead. 

Read More

Which ASX companies are resurrecting abandoned drugs? Part 3

Apr 18th, 2024

DEP is based on dendrimers, which are highly branched polymers, to enhance the delivery of cancer treatments and reduce toxic side effects such as neutropenia, nausea, severe diarrhoea and hair loss from chemotherapy agents. Read the full article in The Australian Business Review. 

Read More

Breaking new ground via an oncology treatment tech venture

Apr 9th, 2024

Cheryl Maley, CEO of Starpharma (SPL), provides insight into the partnreship with Medicxi, materialising in Petalion Therapeutics in the UK. 

Read More

Sign up to receive news here